Can-Fite BioPharma (CANF) Interest & Investment Income (2014 - 2019)
Can-Fite BioPharma's (CANF) quarterly Interest & Investment Income came in at $3.0 million in Q4 2019, up 2186.3% YoY from $133228.3 in Q4 2018, and up 11181.48% on a QoQ basis from $27000.0 in Q3 2019.
Can-Fite BioPharma (CANF) Interest & Investment Income (2014 - 2019) Analysis & Trends
Can-Fite BioPharma (CANF) has 6 years of Interest & Investment Income data on file, last reported at $3.0 million in Q4 2019.
- Quarterly Interest & Investment Income rose 2186.3% year-over-year to $3.0 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $3.1 million (up 5996.08% YoY) and the FY2019 annual result came in at $3.1 million, up 5996.08% from the prior year.
- Interest & Investment Income climbed to $3.0 million in Q4 2019, from $27000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $3.0 million in Q4 2019 to a low of -$833000.0 in Q1 2015.
- A 5-year average of $203050.0 and a median of -$7500.0 in 2018 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2016 — Interest & Investment Income jumped 2570.31% — and 2018, when it slumped 4005.56%.
- Tracing CANF's Interest & Investment Income over 5 years: stood at -$64000.0 in 2015, then jumped by 2570.31% to $1.6 million in 2016, then dropped by 29.54% to $1.1 million in 2017, then plunged by 113.11% to -$146000.0 in 2018, then surged by 2186.3% to $3.0 million in 2019.
- The last three Interest & Investment Income figures came in at $3.0 million (Q4 2019), $27000.0 (Q3 2019), and $45000.0 (Q2 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 3.05 Mn |
| Sep 30, 2019 | 27,000.00 |
| Jun 30, 2019 | 45,000.00 |
| Mar 31, 2019 | -9,000.00 |
| Dec 31, 2018 | -146,000.00 |
| Sep 30, 2018 | -739,000.00 |
| Jun 30, 2018 | 942,000.00 |
| Mar 31, 2018 | -6,000.00 |
| Dec 31, 2017 | 1.11 Mn |
| Sep 30, 2017 | -18,000.00 |
| Jun 30, 2017 | -669,000.00 |
| Mar 31, 2017 | 206,000.00 |
| Dec 31, 2016 | 1.58 Mn |
| Sep 30, 2016 | -229,000.00 |
| Jun 30, 2016 | -479,000.00 |
| Mar 31, 2016 | -499,000.00 |
| Dec 31, 2015 | -64,000.00 |
| Sep 30, 2015 | 724,000.00 |
| Jun 30, 2015 | 67,000.00 |
| Mar 31, 2015 | -833,000.00 |